TreatmentTrends

November 2012

TreatmentTrends®: Pneumonia (US) 2012

Introduction:

This report provides insight into the management of patients with community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator- associated pneumonia (VAP), and health care-associated pneumonia (HCAP) in the hospital setting and analyzes the hospital antibiotic prescribing practices for the treatment of pneumonia due to emerging and clinically-important pathogens, including MRSA and Pseudomonas aeruginosa. TreatmentTrends® is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice patterns, attitudes and perceptions, unmet needs, and projected use of antibiotics in the hospital setting. These studies also explore the perceived advantages and disadvantages of currently available therapies and therapies in development.

Questions Answered in This Report:

  *   Understand how physicians make treatment choices for pneumonia, including choosing empiric treatment and assessment of patients’ risk for infections due to clinically-important and drug-resistant pathogens


  *   Determine which patient subpopulations are difficult-to-treat and identify key areas of need with respect to pneumonia


  *   Understand the pneumonia patient populations treated in the hospital with respect to age, gender, treatment hospital demographics, risk factors, comorbidities, and treatment outcomes including readmissions


  *   Evaluate treatment of the key pathogens (including drug-resistant strains) associated with nosocomial pneumonia understand which pathogens are of concern to physicians, and which pose new treatment challenges and drug development opportunities


  *   Understand physicians' preference for therapies and analyze factors and drug attributes that influence their current and future prescribing patterns


  *   Understand ID physicians’ receptivity to novel and developing therapies and therapeutic approaches

Scope:

Sample Frame & Methodology:

- Over 100 hospital-based physicians, which include at least 50 infectious diseases specialists and 50 critical care/ICU/pulmonary disease specialists complete a 45-minute online quantitative survey with several openended questions for qualitative feedback

- Respondents have at least 50% of their practice in the hospital, patient-based.

- Minimum of 2 years of post-residency experience and a maximum of 30 years in practice

Deliverables:

- Final report in PowerPoint

- Complete set of frequency tables and standard cross tabulations

- Clients committing to the project prior to fielding will be invited to comment on the survey tool and may include up to three proprietary questions in the physician survey

Product Coverage:

PIPERACILLIN-TAZOBACTAM, CARBAPENEMS, FLUOROQUINOLONES, TIGECYCLINE, CEFTAZIDIME, CEFEPIME, CEFTRIAXONE, COLISTIN, AMINOGLYCOSIDES, CEFTAROLINE, VANCOMYCIN, LINEZOLID, TELAVANCIN, AND OTHER SERIOUS GRAM-POSITIVE AGENTS

PHASE II AND III PRODUCTS IN DEVELOPMENT

Related 2012 Products:

- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)

- TreatmentTrends®: Gram-Negative Infections (US)

- TreatmentTrends®: Gram-Negative Infections (EU)

- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US)

- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)

- LaunchTrends®: Teflaro

Search Published Reports


Decision Resources Group brands include: